How Guardant360 CDx detects ESR1 mutations before breast cancer progresses on imaging
Guardant360 CDx gains European CE marking for ETCAMAH patient selection. See how ESR1 blood testing changes advanced breast cancer treatment.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy
Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.
Medical Devices & Diagnostics
Geneoscopy’s ColoSense Medicare win puts stool RNA testing into the colorectal screening mainstream
Medicare coverage gives ColoSense a bigger test: can stool RNA screening move from FDA approval to real colorectal cancer adoption?
Medical Devices & Diagnostics
Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Medical Devices & Diagnostics
Guardant Health and Merck sign global deal to co-develop cancer companion diagnostics
Guardant Health and Merck announce global CDx collaboration using Infinity Smart liquid biopsy platform. Find out what this means for oncology drug development.
Pharma & Biotech
Can Guardant Health and Trial Library fix the clinical trial inclusion gap with AI and genomics?
Guardant Health and Trial Library team up to improve cancer trial access using AI and genomic data. Discover how this could reshape enrollment and equity in oncology.
Medical Devices & Diagnostics
Guardant and Gemelli bring precision oncology in-house: What it means for EU care delivery
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.